Literature DB >> 15719207

Reduced fracture risk in users of thiazide diuretics.

L Rejnmark1, P Vestergaard, L Mosekilde.   

Abstract

Thiazide diuretics (TD) reduce renal calcium excretion and may increase bone mineral density. A reduced fracture risk has been reported in some but not all studies. The aim of this study was to assess fracture risk in users of TD. The study design was nationwide population-based pharmacoepidemiological case-control study with fracture in year 2000 as outcome and use of TD during the previous 5 years as the exposure variable. Individual use of TD was derived from the Danish National Pharmacological Database and related to fracture data from the National Hospital Discharge Register. These data were combined with information on use of other drugs, social status, working status, income, educational status, contacts with general practitioners and practicing specialists, and comorbidity. A total of 64,699 patients (age = 40 years) who sustained a fracture during the year 2000 were compared to 194,111 age- and gender-matched controls. After adjustment for potential confounders, current use of TD was associated with a 10% (95% confidence interval [CI], 7% to 12%) reduced risk of any fracture and a 17% (95% CI 11% to 23%) reduced risk of forearm fractures. In former TD users, the risk reduction was slightly less pronounced. Similar results were found in men and women, and in subjects younger or > or = 65 years of age. Dose-effect analysis revealed a decreased risk of any fracture and fractures at the forearm and hip with an increased number of redeemed defined daily dosages (DDDs) of TD. Therefore, use of more than 2000 DDD was associated with a 19% (95% CI 10% to 27%) decreased hip fracture risk. We conclude that use of TD is associated with a significantly reduced fracture risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719207     DOI: 10.1007/s00223-004-0084-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  24 in total

Review 1.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

2.  Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial.

Authors:  Karen L Margolis; Lisa Palermo; Eric Vittinghoff; Gregory W Evans; Hal H Atkinson; Bruce P Hamilton; Robert G Josse; Patrick J O'Connor; Debra L Simmons; Margaret Tiktin; Ann V Schwartz
Journal:  J Gen Intern Med       Date:  2014-08-16       Impact factor: 5.128

3.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

Review 4.  Strategies for the prevention and control of osteoporosis in developing countries.

Authors:  Jorge Morales-Torres
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

5.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

6.  Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.

Authors:  C Kruse; P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

7.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.

Authors:  B Abrahamsen; K H Rubin; P A Eiken; R Eastell
Journal:  Osteoporos Int       Date:  2012-10-16       Impact factor: 4.507

8.  Risk of endometrial cancer in relation to medical conditions and medication use.

Authors:  Joan Fortuny; Camelia Sima; Sharon Bayuga; Homer Wilcox; Katherine Pulick; Shameka Faulkner; Ann G Zauber; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

Review 9.  [Pharmacogenic osteoporosis beyond cortisone. Proton pump inhibitors, glitazones and diuretics].

Authors:  P H Kann; P Hadji; R S Bergmann
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

10.  Diuretic Use and Risk of Vertebral Fracture in Women.

Authors:  Julie M Paik; Harold N Rosen; Catherine M Gordon; Gary C Curhan
Journal:  Am J Med       Date:  2016-08-16       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.